- Nanologica ABSenior Director Marketing and Business DevelopmentPHARMACEUTICALS INDUSTRYAugust 2021 - December 2023 (2 years and 5 months)Stockholm, SwedenLed Business Development, New Product Planning and Commercialization of a novel drug delivery technology platform with focus on applications in Biologics and Rare Diseases. Member of the corporate management team.Developed and implemented a new focused strategy with a new direction for the business area focusing on where the technology has its highest potential, balancing unmet needs, business opportunity and risks. To deliver on the strategy most effectively I have developed a road map clearly describing the way forward to clinic. I have also developed multiple brand strategies (including TPP, positioning, value proposition, business case etc.) for potential opportunities to assess product potentials and make priorities.
- AstraZenecaGlobal Senior Director, Biopharmaceutical Business UnitPHARMACEUTICALS INDUSTRYApril 2017 - July 2021 (4 years and 4 months)Gothenburg, SwedenLed the Global Device strategy for AstraZeneca’s inhaled portfolio, as well as the commercial part in the development of future inhalation devices, formulations, and platforms. Developed a Digital Health launch strategy and defined business models as well as developed a ROI model to assess suitable markets and business models for Digital Health launch.Appointed to lead several Workstreams in the Global Therapeutic Area and Disease Strategy.As member of the Core Global Project Team for Established Brands and Nebulisation I was engaged as subject matter expert with regards to the established brands portfolio. Commercial lead in all Business Development evaluations in the inhalation space. Member of the Global Sustainability team, deeply involved in all matters regarding the environmental aspects of AstraZeneca’s inhaled drug products cross the respiratory portfolio.
- AstraZenecaGlobal Director, Global Product and Portfolio StrategyPHARMACEUTICALS INDUSTRYAugust 2014 - March 2017 (2 years and 8 months)Gothenburg, SwedenGlobal lead for a portfolio of six brands, worth $1.5bn annual sales combined. The biggest brand, Pulmicort®, grew under my leadership from flat $850mn to $1.2bn with double digit growth in three years by developing and implementing a new business model for Nebulised treatment. Led a cross-functional Global Project Team for the portfolio and member of the Core Global Project Team. Commercial lead in all Business Development evaluations and New Product Planning in the TA.Led the Global Device strategy for AstraZeneca’s inhaled portfolio. Commercial lead for all inhaler devices and formulations cross AZ commercialized portfolio as well as leading the commercial part for development of future inhalation devices, formulations, and platforms.
- Master of Science in Business AdministrationUniversity of Lund1996